FAST-MOVING LIVES DEMAND THE FASTEST SERIES COMPLETION"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1,2
Only BEXSERO can help protect your patients from MenB in as fast as 1 month with 2 doses
BEXSERO combines 4 different antigenic components"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1, each targeting a different mechanism related to MenB survival and disease development
Vaccination may not protect all recipients.
The persons depicted are models used for illustrative purposes only.
BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals 10 through 25 years of age.
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.